Page Header Image

June 11, 2019

InGeneron Extends Series D Financing to $43 Million to Bring Regenerative Cell Therapy into the Clinic

Houston, TX, USA – Company raises up to additional $23 million from strategic partner Sanford Health to advance pivotal program in rotator cuff tendinopathy.

Read more

May 15, 2019

InGeneron Initiates Pivotal Study for its Clinical Lead Program in Rotator Cuff Tendinopathy

Houston, TX, USA – Company enrolls first patients in multi-center trial evaluating regenerative cell therapy at the point of care for partial rotator cuff tears.

Read more

March 21, 2019

InGeneron Announces Publication of Results from First-in-Human Case Report of its Cell Therapy in Bone Regeneration

Houston, TX, USA – Autologous point-of-care regenerative cell therapy shows favorable safety profile and promising histological outcome in clinical case study of guided bone regeneration.

Read more

January 23, 2019

InGeneron Expands Development Pipeline with Two Osteoarthritis Programs

Houston, TX, USA – Company enrolls first patients in feasibility studies for chronic back pain and wrist osteoarthritis, setting clinical development focus on orthopedic indications.

Read more

December 12, 2018

InGeneron Reports Positive Top-Line Data From its Clinical Lead Program in Rotator Cuff Tendinopathy

Houston, TX, USA – Feasibility study meets primary endpoints and paves the way for a pivotal study in 2019.

Read more

October 4, 2017

InGeneron Appoints Angelo Moesslang as Chief Executive Officer

Houston, TX, USA and Munich, Germany – InGeneron announced today that Angelo Moesslang, PhD, former Chief Financial Officer (CFO) of Fresenius Medical Care North America, has joined InGeneron and will serve as the new Chief Executive Officer (CEO).

Read more

September 18, 2017

InGeneron Announces Publication of Positive Results from Investigator-Initiated Wound Healing Case Series Using Company’s Regenerative Cell Technology

Houston, TX, USA and Munich, Germany – Point-of-care regenerative cell therapy demonstrates promising safety and tolerability profile and closure of venous chronic leg wounds as conducted by Technical University Munich.

Read more

March 6, 2017

InGeneron Completes Strategic Financing from Sanford Health to Advance Regenerative Cell Therapies

Houston, Texas, and Sioux Falls, South Dakota – In addition to clinical trial cooperation with one of the largest U.S. hospital groups, investment will support clinical development in orthopedics and wound healing.

Read more

February 14, 2017

Changes in Management Team

Houston, TX, USA – InGeneron, Inc. today announced changes in its leadership team. Michael Coleman, PhD, has stepped down as President and CEO and will join InGeneron’s Scientific Advisory Board. Ron Stubbers, MBA, formerly InGeneron’s Vice President of Operations, has been appointed President. The company also announced the appointment of Glenn Winnier, PhD, as Chief Scientific Officer.

Read more

December 5, 2016

InGeneron Establishes Presence in Cambridge, MA and Initiates Collaboration with German Accelerator Life Sciences

Cambridge, MA, USA and Berlin, Germany – InGeneron, a regenerative medicine and biotechnology company, today announced its acceptance to the German Accelerator Life Sciences (GALS) program, an initiative supported by the German Federal Ministry for Economic Affairs and Energy (BMWi).

Read more

November 21, 2016

InGeneron Announces Presentation of Results from Investigator Initiated Case Series of its Regenerative Cell Therapy in Chronic Back Pain at IFATS

Houston, TX, USA and Munich, Germany – InGeneron, Inc. today announced the presentation of initial data from an investigator initiated case series using its proprietary adipose-derived regenerative cell (ADRC) technology for the treatment of facet joint syndrome, one of the major causes of chronic back pain.

Read more